Literature DB >> 30954640

Update on immunogenicity in severe asthma: Experience with mepolizumab.

Hector G Ortega1, Erik Meyer2, Guy Brusselle3, Koichiro Asano4, Charlene M Prazma5, Frank C Albers5, Stephen A Mallett6, Steve W Yancey5, Gerald J Gleich7.   

Abstract

Entities:  

Year:  2019        PMID： 30954640     DOI： 10.1016/j.jaip.2019.03.042

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  2 in total

1.  Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study.

Authors:  Shoko Isoyama; Nobuhisa Ishikawa; Kosuke Hamai; Mirai Matsumura; Hiroki Kobayashi; Akio Nomura; Sayaka Ueno; Takuya Tanimoto; Hiroyuki Maeda; Hiroshi Iwamoto; Noboru Hattori
Journal:  Intern Med       Date:  2022-06-01       Impact factor: 1.282

Review 2.  Severe Eosinophilic Asthma.

Authors:  Agamemnon Bakakos; Stelios Loukides; Petros Bakakos
Journal:  J Clin Med       Date:  2019-09-02       Impact factor: 4.241
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.